Document:

Exhibit
10.1

 

FORWARD
SHARE PURCHASE AGREEMENT

 

This
Forward Share Purchase Agreement (this “Agreement”) is entered into as of October 12, 2021, by and among Big
Cypress Acquisition Corp., a Delaware corporation (“BCYP”), and Radcliffe SPAC Master Fund, L.P., a Cayman
Islands exempted limited partnership (“Radcliffe”).

 

R
E C I T A L S

 

WHEREAS,
BCYP is a blank check company incorporated in Delaware for the purpose of effecting a merger, share exchange, asset acquisition, share
purchase, reorganization or similar business combination with one or more businesses;

 

WHEREAS,
BCYP has entered into an Agreement and Plan of Merger, dated as of June 21, 2021, with SAB Biotherapeutics, Inc., a Delaware corporation
(“SAB”), for the purpose of effecting a combination with SAB, and BCYP has filed a proxy statement/prospectus
with the Securities and Exchange Commission that seeks, among other things, stockholder approval of the proposed business combination
with SAB (the “Business Combination”); and

 

WHEREAS,
the parties wish to enter into this Agreement, pursuant to which BCYP shall purchase from Radcliffe, and Radcliffe shall sell and transfer
to BCYP, shares of common stock, par value $0.0001 per share (“Common Stock”), of BCYP (the “Shares”)
held by Radcliffe immediately prior to the closing of the Business Combination on the terms and conditions set forth herein.

 

NOW,
THEREFORE, in consideration of the premises, representations, warranties and the mutual covenants contained in this Agreement, and for
other good and valuable consideration, the receipt, sufficiency and adequacy of which are hereby acknowledged, the parties hereto agree
as follows:

 

1.
Purchase and Sale; Closing.

 

1.1.
Forward Share Purchase. Subject to the conditions and timing set forth in this Section 1, Radcliffe shall sell and transfer
to BCYP, and BCYP shall purchase from Radcliffe, up to 1,390,000 Shares that are actually owned by Radcliffe at the closing of the Business
Combination at a per Share price (the “Purchase Price”) equal to $10.10 per Share. For the avoidance of any
doubt, Radcliffe shall not be required to purchase Shares if any such purchase would cause Radcliffe to beneficially own in excess of
9.90% of the then-issued and outstanding shares of Common Stock.

 

1.2.
Closing. BCYP shall purchase the Shares on the later of (a) the first business day following the ninetieth (90th) day
after the closing of the Business Combination and (b) the first business day following the ninety fifth (95th) day after the
closing of the Business Combination if BCYP directs Radcliffe to sell shares pursuant to Section 1.4(b) (the “Closing
Date”). No later than two Business Days before the Closing Date, Radcliffe shall deliver a written notice to BCYP specifying
the number of Shares that BCYP is required to purchase, the aggregate Purchase Price and instructions for wiring the Purchase Price to
Radcliffe. The closing of the sale of the Shares (the “Closing”) shall occur on the Closing Date. On the Closing
Date, Radcliffe shall deliver the Shares to BCYP against receipt of the Purchase Price. For purposes of this Agreement, “Business
Day” means any day, other than a Saturday or a Sunday, that is neither a legal holiday nor a day on which banking institutions
are generally authorized or required by law or regulation to close in New York, New York and Sioux Falls, South Dakota.

 

    	 

     

    

 

1.3.
Lock-up; Non-Redemption.

 

(a)
Except as set forth in Section 1.4, Radcliffe agrees to continue to hold, and not to offer, sell, contract to sell, pledge, transfer,
assign, or otherwise dispose of, directly or indirectly, or hedge any Shares (including any transactions involving any derivative securities
of BCYP and including any Short Sales (as defined below) involving any of BCYP’s securities) until the Closing Date.

 

(b)
Radcliffe irrevocably and unconditionally hereby agrees that Radcliffe shall not, and shall cause its affiliates not to, redeem or
otherwise tender or submit for redemption any of its securities pursuant to or in connection with the Business
Combination.

 

(c)
For purposes hereof, “Short Sales” include, without limitation, all “short sales” as defined in Rule 200 promulgated
under Regulation SHO under the securities and Exchange Act of 1934 (the “Exchange Act”), whether or not against the box,
and all types of direct and indirect stock pledges, forward sales contracts, options, puts, calls, short sales, swaps, “put equivalent
positions” (as defined in Rule 16a-1(h) under the Exchange Act) and similar arrangements (including on a total return basis), and
sales and other transactions through non-U.S. broker dealers or foreign regulated brokers.

 

1.4.
Open Market Sales.

 

(a)
Notwithstanding anything to the contrary herein, the parties agree that Radcliffe shall, after the closing of the Business Combination,
have the right but not the obligation to sell any or all of its Shares into in the open market if the share price equals or exceeds $10.10
per Share (the “Market Sale Price”). In furtherance of the foregoing, Radcliffe shall have the right to sell
such Shares at any time provided that the price received by Radcliffe (not including any commissions due by Radcliffe for the sale) is
at least the Market Sale Price.

 

(b)
Notwithstanding anything to the contrary herein, upon the prior written approval of BCYP Radcliffe may sell any or all of its Shares
into in the open market on the terms mutually agreed upon by BCYP and Radcliffe.

 

1.5.
Escrow. Upon the closing of the Business Combination, BCYP will direct Continental Stock Transfer & Trust Company (the Trustee
under the Trust Agreement, dated as of January 11, 2021 that was entered into by BCYP in connection with its initial public offering)
to transfer from the initial public offering trust, and to an escrow agent reasonably acceptable to Radcliffe, an amount equal to the
product of (x) $10.10 and (y) the number of unredeemed Shares owned by Radcliffe prior to 5:00 P.M., Eastern Time, On October 18, 2021.

 

2.
Consideration. Within five days of the execution of this Agreement, BCYP shall pay to Radcliffe an amount equal to $50,000, by
wire transfer of immediately available funds to an account specified by Radcliffe.

 

    	2

     

    

 

3.
Representations and Warranties of Radcliffe. Radcliffe represents and warrants to BCYP as follows, as of the date hereof:

 

3.1.
Organization and Power. Radcliffe is duly organized, validly existing, and in good standing under the laws of the jurisdiction
of its formation and has all requisite power and authority to carry on its business as presently conducted and as proposed to be conducted.

 

3.2.
Authorization. Radcliffe has full power and authority to enter into this Agreement. This Agreement, when executed and delivered
by Radcliffe will constitute the valid and legally binding obligation of Radcliffe enforceable against it in accordance with its terms,
except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of general
application affecting enforcement of creditors’ rights generally, or (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies.

 

3.3.
Governmental Consents and Filings. No consent, approval, order or authorization of, or registration, qualification, designation,
declaration or filing with, any federal, state or local governmental authority is required on the part of Radcliffe in connection with
the consummation of the transactions contemplated by this Agreement.

 

3.4.
Compliance with Other Instruments. The execution, delivery and performance by Radcliffe of this Agreement and the consummation
by Radcliffe of the transactions contemplated by this Agreement will not result in any violation or default (i) of any provisions of
its organizational documents, (ii) of any instrument, judgment, order, writ or decree to which it is a party or by which it is bound,
(iii) under any note, indenture or mortgage to which it is a party or by which it is bound, (iv) under any lease, agreement, contract
or purchase order to which it is a party or by which it is bound or (v) of any provision of federal or state statute, rule or regulation
applicable to Radcliffe, in each case (other than clause (i)), which would have a material adverse effect on Radcliffe or its ability
to consummate the transactions contemplated by this Agreement.

 

3.5.
Share Holdings. As of October 11, 2021, Radcliffe held 297,583 Shares, none of which have been sold, offered or contracted to
be sold, pledged, transferred, assigned or otherwise disposed of, directly or indirectly, or hedged, since such date; except that the
Shares may be held in portfolio margin account(s) at its prime brokers

 

3.6.
Disclosure of Information. Radcliffe has had an opportunity to discuss BCYP’s business, management, financial affairs and
the terms and conditions of this Agreement, as well as the terms of the Business Combination, with BCYP’s management.

 

3.7.
No Other Representations and Warranties; Non-Reliance. Except for the specific representations and warranties contained in this
Section 3 and in any certificate or agreement delivered pursuant hereto, neither Radcliffe or any person acting on behalf of Radcliffe
nor any of Radcliffe’s affiliates (the “Radcliffe Parties”) has made, makes or shall be deemed to make
any other express or implied representation or warranty with respect to Radcliffe and this offering, and the Radcliffe Parties disclaim
any such representation or warranty. Except for the specific representations and warranties expressly made by BCYP in Section 4
of this Agreement and in any certificate or agreement delivered pursuant hereto, the Radcliffe Parties specifically disclaim that they
are relying upon any other representations or warranties that may have been made by BCYP, any person on behalf of BCYP or any of BCYP’s
affiliates (collectively, the “BCYP Parties”).

 

    	3

     

    

 

4.
Representations and Warranties of BCYP. BCYP represents and warrants to Radcliffe as follows:

 

4.1.
Organization and Corporate Power. BCYP is a corporation duly incorporated and validly existing and in good standing as a corporation
under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as presently conducted
and as proposed to be conducted. BCYP has no subsidiaries.

 

4.2.
Authorization. All corporate action required to be taken by BCYP’s Board of Directors in order to authorize BCYP to enter
into this Agreement has been taken or will be taken prior to the Closing. All action on the part of the directors and officers of BCYP
necessary for the execution and delivery of this Agreement, the performance of all obligations of BCYP under this Agreement to be performed
as of the Closing, has been taken or will be taken prior to the Closing. This Agreement, when executed and delivered by BCYP, shall constitute
the valid and legally binding obligation of BCYP, enforceable against BCYP in accordance with its terms except (i) as limited by applicable
bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting
the enforcement of creditors’ rights generally, or (ii) as limited by laws relating to the availability of specific performance,
injunctive relief, or other equitable remedies.

 

4.3.
Disclosure. BCYP has previously disclosed to Radcliffe material non-public information with respect to BCYP, which information
has now been publicly disclosed by BCYP.

 

4.4.
Governmental Consents and Filings. Assuming the accuracy of the representations made by Radcliffe in this Agreement, no consent,
approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local
governmental authority is required on the part of BCYP in connection with the consummation of the transactions contemplated by this Agreement,
other than BCYP is required to file disclosure reports regarding such transactions in accordance with the terms of the Exchange Act (as
defined below).

 

4.5.
Compliance with Other Instruments. The execution, delivery and performance of this Agreement and the consummation of the transactions
contemplated by this Agreement will not result in any violation or default (i) of any provisions of the certificate of incorporation,
bylaws or other governing documents of BCYP, (ii) of any instrument, judgment, order, writ or decree to which BCYP is a party or by which
it is bound, (iii) under any note, indenture or mortgage to which BCYP is a party or by which it is bound, (iv) under any lease, agreement,
contract or purchase order to which BCYP is a party or by which it is bound or (v) of any provision of federal or state statute, rule
or regulation applicable to BCYP, in each case (other than clause (i)) which would have a material adverse effect on BCYP or its ability
to consummate the transactions contemplated by this Agreement.

 

    	4

     

    

 

4.6.
Adequacy of Financing. BCYP will have available to it at all times sufficient funds to satisfy its obligations under this Agreement.

 

4.7.
No Other Representations and Warranties; Non-Reliance. Except for the specific representations and warranties contained in this
Section 4 and in any certificate or agreement delivered pursuant hereto, none of BCYP Parties has made, makes or shall be deemed
to make any other express or implied representation or warranty with respect to BCYP or the Business Combination, and BCYP Parties disclaim
any such representation or warranty. Except for the specific representations and warranties expressly made by Radcliffe in Section
3 of this Agreement and in any certificate or agreement delivered pursuant hereto, BCYP Parties specifically disclaim that they are
relying upon any other representations or warranties that may have been made by the Radcliffe Parties.

 

4.8.
Exclusivity. BYCP represents that it has not and will not enter into any similar agreements to this Agreement with any other parties
prior to the consummation of the Business Combination.

 

5.
Closing Conditions.

 

5.1.
The obligation of BCYP to purchase the Shares at the Closing under this Agreement shall be subject to the fulfillment, at or prior to
the Closing of each of the following conditions, any of which, to the extent permitted by applicable laws, may be waived by BCYP:

 

(a)
The Business Combination shall have been consummated;

 

(b)
The representations and warranties of Radcliffe set forth in Section 3 of this Agreement shall have been true and correct as of
the date hereof and shall be true and correct as of the Closing Date, as applicable, with the same effect as though such representations
and warranties had been made on and as of such date (other than any such representation or warranty that is made by its terms as of a
specified date, which shall be true and correct as of such specified date), except where the failure to be so true and correct would
not have a material adverse effect on BCYP or its ability to consummate the transactions contemplated by this Agreement;

 

(c)
Radcliffe shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required
by this Agreement to be performed, satisfied or complied with by Radcliffe at or prior to the Closing; and

 

5.2.
The obligation of Radcliffe to sell and transfer the Shares at the Closing under this Agreement shall be subject to the fulfillment,
at or prior to the Closing of each of the following conditions, any of which, to the extent permitted by applicable laws, may be waived
by Radcliffe:

 

(a)
The Business Combination shall have been consummated;

 

(b)
All filings that BCYP is required to make under the Exchange Act shall be current, true and accurate.

 

    	5

     

    

 

(c)
The representations and warranties of BCYP set forth in Section 4 of this Agreement shall have been true and correct as of the
date hereof and shall be true and correct as of the Closing Date, as applicable, with the same effect as though such representations
and warranties had been made on and as of such date (other than any such representation or warranty that is made by its terms as of a
specified date, which shall be true and correct as of such specified date), except where the failure to be so true and correct would
not have a material adverse effect on Radcliffe or its ability to consummate the transactions contemplated by this Agreement;

 

(d)
BCYP shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by
this Agreement to be performed, satisfied or complied with by BCYP at or prior to the Closing; and

 

(e)
No order, writ, judgment, injunction, decree, determination, or award shall have been entered by or with any governmental, regulatory,
or administrative authority or any court, tribunal, or judicial, or arbitral body, and no other legal restraint or prohibition shall
be in effect, preventing the sale and transfer by Radcliffe of the Shares.

 

6.
Termination.

 

6.1.
This Agreement may be terminated at any time prior to the Closing:

 

(a)
by mutual written consent of BCYP and Radcliffe;

 

(b)
automatically if the stockholders fail to approve the Business Combination; and by Radcliffe by giving written notice to BCYP on the
date that is one Business Day prior to the Closing Date.

 

6.2.
For the avoidance of doubt, in the event this Agreement is terminated, Radcliffe shall not be restricted with respect to its ability
to dispose of the Shares after the termination date of this Agreement. This Agreement shall forthwith become null and void and have no
effect, without any liability on the part of Radcliffe or BCYP and their respective directors, officers, employees, partners, managers,
members, or stockholders and all rights and obligations of each party shall cease; provided, however, that nothing contained
in this Section 6 shall relieve either party from liabilities or damages arising out of any fraud or willful breach by such party
of any of its representations, warranties, covenants or agreements contained in this Agreement.

 

7.
General Provisions.

 

7.1.
Notices.

 

(a)
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given
upon the earlier of actual receipt, or (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail or
facsimile (if any) during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s
next Business Day, (c) five (5) Business Days after having been sent by registered or certified mail, return receipt requested, postage
prepaid, or (d) one (1) Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next Business
Day delivery, with written verification of receipt.

 

    	6

     

    

 

(b)
All communications sent to BCYP shall be sent to:

 

Big
Cypress Acquisition Corp.

300
W. 41st Street, Suite 202

Miami
Beach, Florida 33140

Attention:
Samuel J. Reich

Email:
sam@bigcypressaccorp.com

 

and

 

SAB
Biotherapeutics, Inc.

2100
East 54th Street North

Sioux
Falls, SD 57104

Attention:
Eddie Sullivan

Email:
Esullivan@sabbiotherapeutics.com

 

with
a copy (which shall not constitute notice) to:

 

Dentons
US LLP

1221
Avenue of the Americas

New
York, NY 10020

Attention:
Ilan Katz and Brian Lee

Email:
ilan.katz@dentons.com and brian.lee@dentons.com

 

(c)
All communications to Radcliffe shall be sent to:

 

c/o
Radcliffe Capital Management, L.P.

50
Monument Road, Suite 300

Bala
Cynwyd, PA 19004

Attention:
General Counsel

Email
lbest@radcliffefunds.com

with
a copy to: ops@radcliffefunds.com

 

or
to such e-mail address, facsimile number (if any) or address as subsequently modified by written notice given in accordance with this
Section 7.1.

 

7.2.
No Finder’s Fees. Each party represents that neither party will be obligated for any finder’s fee or commission in
connection with this transaction.

 

7.3.
Survival of Representations and Warranties. All of the representations and warranties contained herein shall survive the Closing.

 

7.4.
Entire Agreement. This Agreement, together with any documents, instruments and writings that are delivered pursuant hereto or
referenced herein, constitute the entire agreement and understanding of the parties hereto in respect of its subject matter and supersedes
all prior understandings, agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in
any way to the subject matter hereof or the transactions contemplated hereby.

 

    	7

     

    

 

7.5.
Successors. All of the terms, agreements, covenants, representations, warranties, and conditions of this Agreement are binding
upon, and inure to the benefit of and are enforceable by, the parties hereto and their respective successors. Nothing in this Agreement,
express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any
rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

7.6.
Assignments. Except as otherwise specifically provided herein, no party hereto may assign either this Agreement or any of its
rights, interests, or obligations hereunder without the prior written approval of the other party.

 

7.7.
Counterparts. This Agreement may be executed in two or more counterparts, each of which will be deemed an original but all of
which together will constitute one and the same instrument.

 

7.8.
Headings. The section headings contained in this Agreement are inserted for convenience only and will not affect in any way the
meaning or interpretation of this Agreement.

 

7.9.
Governing Law. This Agreement, the entire relationship of the parties hereto, and any litigation between the parties (whether
grounded in contract, tort, statute, law or equity) shall be governed by, construed in accordance with, and interpreted pursuant to the
laws of the State of Delaware, without giving effect to its choice of laws principles.

 

7.10.
Jurisdiction. The parties (i) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Delaware
and to the jurisdiction of the United States District Court for Delaware for the purpose of any suit, action or other proceeding arising
out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this
Agreement except in state courts of Delaware or the United States District Court for the Delaware, and (c) hereby waive, and agree not
to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally
to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action
or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement
or the subject matter hereof may not be enforced in or by such court.

 

7.11.
Waiver of Jury Trial. The parties hereto hereby waive any right to a jury trial in connection with any litigation pursuant to
this Agreement and the transactions contemplated hereby.

 

7.12.
Amendments. This Agreement may not be amended, modified or waived as to any particular provision, except with the prior written
consent of BCYP and Radcliffe.

 

7.13.
Severability. The provisions of this Agreement will be deemed severable and the invalidity or unenforceability of any provision
will not affect the validity or enforceability of the other provisions hereof; provided that if any provision of this Agreement, as applied
to any party hereto or to any circumstance, is adjudged by a governmental authority, arbitrator, or mediator not to be enforceable in
accordance with its terms, the parties hereto agree that the governmental authority, arbitrator, or mediator making such determination
will have the power to modify the provision in a manner consistent with its objectives such that it is enforceable, and/or to delete
specific words or phrases, and in its reduced form, such provision will then be enforceable and will be enforced.

 

    	8

     

    

 

7.14.
Expenses. Each of BCYP and Radcliffe will bear its own costs and expenses incurred in connection with the preparation, execution
and performance of this Agreement and the consummation of the transactions contemplated hereby, including all fees and expenses of agents,
representatives, financial advisors, legal counsel and accountants.

 

7.15.
Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. If an ambiguity
or question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the parties hereto and no presumption
or burden of proof will arise favoring or disfavoring any party hereto because of the authorship of any provision of this Agreement.
Any reference to any federal, state, local, or foreign law will be deemed also to refer to law as amended and all rules and regulations
promulgated thereunder, unless the context requires otherwise. The words “include,” “includes,” and “including”
will be deemed to be followed by “without limitation.” Pronouns in masculine, feminine, and neuter genders will be construed
to include any other gender, and words in the singular form will be construed to include the plural and vice versa, unless the context
otherwise requires. The words “this Agreement,” “herein,” “hereof,” “hereby,” “hereunder,”
and words of similar import refer to this Agreement as a whole and not to any particular subdivision unless expressly so limited. The
parties hereto intend that each representation, warranty, and covenant contained herein will have independent significance. If any party
hereto has breached any representation, warranty, or covenant contained herein in any respect, the fact that there exists another representation,
warranty or covenant relating to the same subject matter (regardless of the relative levels of specificity) which such party hereto has
not breached will not detract from or mitigate the fact that such party hereto is in breach of the first representation, warranty, or
covenant.

 

7.16.
Waiver. No waiver by any party hereto of any default, misrepresentation, or breach of warranty or covenant hereunder, whether
intentional or not, may be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant
hereunder or affect in any way any rights arising because of any prior or subsequent occurrence.

 

7.17.
Specific Performance. Each party agrees that irreparable damage may occur in the event any provision of this Agreement was not
performed by the other party in accordance with the terms hereof and that the other party shall be entitled to seek specific performance
of the terms hereof, in addition to any other remedy at law or equity.

 

(Signature
page follows)

 

    	9

     

    

 

IN
WITNESS WHEREOF, the undersigned have executed this Agreement to be effective as of the date first set forth above.

 

	 	BIG
    CYPRESS ACQUISITION CORP.
	 	 	 
	 	By:
    	 
	 	Name:
    	Samuel
    J. Reich
	 	Title:
    	Chief
    Executive Officer
	 	 	 
	 	RADCLIFFE
    SPAC MASTER FUND, L.P.
	 	 	 
	 	By:
    	Radcliffe
    Capital Management, L.P., its manager
	 	By:
    	RGC
    Management Company, LLC, its general partner
	 	 	 
	 	By:
    	 
	 	Name:
    	Steven
    Katznelson
	 	Title:	Managing MemberExhibit 10.13

 

XORTX Therapeutics Inc.

 

and

 

Continental Stock Transfer & Trust
Company, as

Warrant Agent

 

 

 

Warrant Agency Agreement

 

Dated as of ________________, 2021

 

WARRANT AGENCY AGREEMENT 

 

WARRANT AGENCY AGREEMENT, dated as of _________, 2021 (“Agreement”),
between XORTX Therapeutics Inc., a British Columbia corporation (the “Company”), and Continental Stock Transfer &
Trust Company, a New York corporation (the “Warrant Agent”).

 

W I T N E S S E T H

 

WHEREAS, pursuant to a registered offering by the Company of
common share units (“Common Units”) consisting of common shares, no par value per share (the “Common
Shares”) and warrants to purchase Common Shares, in the form attached hereto as Exhibit 1 (the “Common
Share Warrants”), as well as pre-funded warrant units (“Pre-funded Units”), consisting of pre-funded
warrants, in the form attached hereto as Exhibit 2 (“Pre-funded Warrants”) to purchase Common Shares
and Warrants, as well as the issuance of warrants to the Underwriters, in the form attached hereto as Exhibit 3 (the “Underwriter
Warrants”, together with the Pre-funded Warrants and the Common Share Warrants, the “Warrants”) pursuant
to an effective registration statement on Form F-1, as amended (File No. 333-258741) (the “Registration Statement”),
the Company wishes to issue the Warrants in book entry form entitling the respective holders of the Warrants (the “Holders”,
which term shall include a Holder’s transferees, successors and assigns and “Holder” shall include, if the Warrants
are held in “street name,” a Participant (as defined below) or a designee appointed by such Participant) to purchase
an aggregate of up to [                ] Common Shares upon the terms and subject to the conditions hereinafter set forth (the “Offering”);

 

WHEREAS, the Common Shares, the Pre-Funded Warrants and the
Warrants to be issued in connection with the Offering shall be immediately separable and will be issued separately, but will be
purchased together in the Offering; and

 

WHEREAS, the Company wishes the Warrant Agent to act on behalf
of the Company, and the Warrant Agent is willing so to act, in connection with the issuance, registration, transfer, exchange,
exercise and replacement of the Warrants and, in the Warrant Agent’s capacity as the Company’s transfer agent, the
delivery of the Warrant Shares (as defined below).

 

NOW, THEREFORE, in consideration of the premises and the mutual
agreements herein set forth, the parties hereby agree as follows:

 

Section 1. Certain Definitions. For purposes of
this Agreement, the following terms have the meanings indicated:

 

(a) “Business Day” means any day except any
Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which the New York Stock Exchange
is authorized or required by law or other governmental action to close.

 

     

     

    

 

(b) “Close of Business” on any given date
means 5:00 p.m., New York City time, on such date; provided, however, that if such date is not a Business Day it
means 5:00 p.m., New York City time, on the next succeeding Business Day.

 

(c) “Person” means an individual, corporation,
association, partnership, limited liability company, joint venture, trust, unincorporated organization, government or political
subdivision thereof or governmental agency or other entity.

 

(d) “Warrant Certificate” means a certificate
issued to a Holder, representing such number of Warrant Shares as is indicated therein.

 

(e) “Warrant Shares” means the Common Shares
underlying the Warrants and issuable upon exercise of the Warrants.

 

All other capitalized terms used but not otherwise defined herein
shall have the meaning ascribed to such terms in the Warrant.

 

Section 2. Appointment of Warrant Agent. The Company
hereby appoints the Warrant Agent to act as agent for the Company in accordance with the terms and conditions hereof, and the Warrant
Agent hereby accepts such appointment. The Company may from time to time appoint a Co-Warrant Agent as it may, in its sole discretion,
deem necessary or desirable. The Warrant Agent shall have no duty to supervise, and will in no event be liable for the acts or
omissions of, any co-Warrant Agent.

 

Section 3. Global Warrants.

 

(a) The Warrants shall be issuable in book entry form (the “Global
Warrants”). All of the Warrants shall initially be represented by one or more Global Warrants deposited with the Warrant
Agent and registered in the name of Cede & Co., a nominee of The Depository Trust Company (the “Depositary”),
or as otherwise directed by the Depositary. Ownership of beneficial interests in the Warrants shall be shown on, and the transfer
of such ownership shall be effected through, records maintained by

(i) the Depositary or its nominee for each Global Warrant
or (ii) institutions that have accounts with the Depositary (such institution, with respect to a Warrant in its account, a
“Participant”).

 

(b) If the Depositary subsequently ceases to make its book-entry
settlement system available for the Warrants, the Company may instruct the Warrant Agent regarding other arrangements for book-entry
settlement. In the event that the Warrants are not eligible for, or it is no longer necessary to have the Warrants available in,
book-entry form, the Warrant Agent shall provide written instructions to the Depositary to deliver to the Warrant Agent for cancellation
each Global Warrant, and the Company shall instruct the Warrant Agent to deliver to each Holder a Warrant Certificate.

 

(c) A Holder has the right to elect at any time or from time
to time a Warrant Exchange (as defined below) pursuant to a Warrant Certificate Request Notice (as defined below). Upon written
notice by a Holder to the Warrant Agent for the exchange of some or all of such Holder’s Global Warrants for a Warrant Certificate
evidencing the same number of Warrants, which request shall be in the form attached hereto as Annex A (a “Warrant
Certificate Request Notice” and the date of delivery of such Warrant Certificate Request Notice by the Holder, the “Warrant
Certificate Request Notice Date” and the deemed surrender upon delivery by the Holder of a number of Global Warrants
for the same number of Warrants evidenced by a Warrant Certificate, a “Warrant Exchange”), the Warrant Agent
shall promptly effect the Warrant Exchange and shall promptly issue and deliver to the Holder a Warrant Certificate for such number
of Warrants in the name set forth in the Warrant Certificate Request Notice. Such Warrant Certificate shall be dated the original
issue date of the Warrants and shall be manually executed by an authorized signatory of the Company. In connection with a Warrant
Exchange, the Company agrees to deliver, or to direct the Warrant Agent to deliver, the Warrant Certificate to the Holder within
three (3) Business Days of the Warrant Certificate Request Notice pursuant to the delivery instructions in the Warrant Certificate
Request Notice (“Warrant Certificate Delivery Date”). If the Company fails for any reason to deliver to the
Holder the Warrant Certificate subject to the Warrant Certificate Request Notice by the Warrant Certificate Delivery Date, the
Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares evidenced
by such Warrant Certificate (based on the VWAP (as defined in the Warrant) of the Common Shares on the Warrant Certificate Request
Notice Date), $10 per Business Day (increasing to $20 per Business Day on the fifth Business Day after such liquidated damages
begin to accrue) for each Business Day after such Warrant Certificate Delivery Date until such Warrant Certificate is delivered
or, prior to delivery of such Warrant Certificate, the Holder rescinds such Warrant Exchange. The Company covenants and agrees
that, upon the date of delivery of the Warrant Certificate Request Notice, the Holder shall be deemed to be the holder of the Warrant
Certificate and, notwithstanding anything to the contrary set forth herein, the Warrant Certificate shall be deemed for all purposes
to contain all of the terms and conditions of the Warrants evidenced by such Warrant Certificate and the terms of this Agreement,
other than Section 3(c), which shall not apply to the Warrants evidenced by a Warrant Certificate. In the event a beneficial
owner requests a Warrant Exchange, upon issuance of the paper Warrant Certificate, the Company shall act as warrant agent and the
terms of the paper Warrant Certificate so issued shall exclusively govern in respect thereof. For purposes of clarity, if there
is a conflict between the express terms of this Agreement and any Warrant Certificate with respect to the terms of the Warrants,
the terms of such Warrant Certificate shall govern and control.

 

     

     

    

 

Section 4. Form of Warrant. The Warrants, together
with the form of election to purchase Common Shares (the “Exercise Notice”) and the form of assignment to be
printed on the reverse thereof, whether a Warrant Certificate or a Global Warrant, shall be substantially in the form of exhibits
hereto.

 

Section 5. Countersignature and Registration. The
Warrants shall be executed on behalf of the Company by its Chief Executive Officer or Chief Financial Officer, either manually
or by facsimile signature, and have affixed thereto the Company’s seal or a facsimile thereof which shall be attested by
the Secretary or an Assistant Secretary of the Company, either manually or by facsimile signature. The Warrants shall be countersigned
by the Warrant Agent either manually or by facsimile signature and shall not be valid for any purpose unless so countersigned.
In case any officer of the Company who shall have signed a Warrant shall cease to be such officer of the Company before countersignature
by the Warrant Agent and issuance and delivery by the Company, such Warrant, nevertheless, may be countersigned by the Warrant
Agent, issued and delivered with the same force and effect as though the person who signed such Warrant had not ceased to be such
officer of the Company; and any Warrant may be signed on behalf of the Company by any person who, at the actual date of the execution
of such Warrant, shall be a proper officer of the Company to sign such Warrant, although at the date of the execution of this Warrant
Agreement any such person was not such an officer.

 

The Warrant Agent will keep or cause to be kept, at one of its
offices, or at the office of one of its agents, books for registration and transfer of the Warrant Certificates issued hereunder.
Such books shall show the names and addresses of the respective Holders of the Warrant Certificates, the number of warrants evidenced
on the face of each of such Warrant Certificate and the date of each of such Warrant Certificate. The Warrant Agent will create
a special account for the issuance of Warrant Certificates.

 

Section 6. Transfer, Split Up, Combination and Exchange
of Warrant Certificates; Mutilated, Destroyed, Lost or Stolen Warrant Certificates. Subject to the provisions of the Warrant
and the last sentence of this first paragraph of Section 6 and subject to applicable law, rules or regulations, or any “stop
transfer” instructions the Company may give to the Warrant Agent, at any time after the closing date of the Offering, and
at or prior to the Close of Business on the Termination Date, any Warrant Certificate or Warrant Certificates or Global Warrant
or Global Warrants may be transferred, split up, combined or exchanged for another Warrant Certificate or Warrant Certificates
or Global Warrant or Global Warrants, entitling the Holder to purchase a like number of Common Shares as the Warrant Certificate
or Warrant Certificates or Global Warrant or Global Warrants surrendered then entitled such Holder to purchase. Any Holder desiring
to transfer, split up, combine or exchange any Warrant Certificate or Global Warrant shall make such request in writing delivered
to the Warrant Agent, and shall surrender the Warrant Certificate or Warrant Certificates to be transferred, split up, combined
or exchanged at the principal office of the Warrant Agent, provided that no such surrender is applicable to the Holder of a Global
Warrant. Any requested transfer of Warrants, whether a Global Warrant or a Warrant Certificate, shall be accompanied by reasonable
evidence of authority of the party making such request that may be required by the Warrant Agent. Thereupon the Warrant Agent shall,
subject to the last sentence of this first paragraph of Section 6, countersign and deliver to the Person entitled thereto
any Warrant Certificate or Global Warrant, as the case may be, as so requested. The Company may require payment from the Holder
of a sum sufficient to cover any tax or governmental charge that may be imposed in connection with any transfer, split up, combination
or exchange of Warrants. The Company shall compensate the Warrant Agent per the fee schedule mutually agreed upon by the parties
hereto and provided separately on the date hereof.

 

     

     

    

 

Upon receipt by the Warrant Agent of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of a Warrant Certificate, which evidence shall include an affidavit of loss,
or in the case of mutilated certificates, the certificate or portion thereof remaining, and, in case of loss, theft or destruction,
of indemnity in customary form and amount, and satisfaction of any other reasonable requirements established by Section 8-405
of the Uniform Commercial Code as in effect in the State of Delaware, and reimbursement to the Company and the Warrant Agent of
all reasonable expenses incidental thereto, and upon surrender to the Warrant Agent and cancellation of the Warrant Certificate
if mutilated, the Company will make and deliver a new Warrant Certificate of like tenor to the Warrant Agent for delivery to the
Holder in lieu of the Warrant Certificate so lost, stolen, destroyed or mutilated.

 

Section 7. Exercise of Warrants; Exercise Price; Termination
Date.

 

(a) The Warrants shall be exercisable commencing on the Initial
Exercise Date. The Warrants shall cease to be exercisable as of the Close of Business on the Termination Date, and all rights to
exercise the Warrants thereunder and under this Agreement shall cease, from and after the Close of Business on the Termination
Date. Subject to the foregoing and to Section 7(b) below, the Holder of a Warrant may exercise the Warrant in whole or in
part upon providing the items required by Section 7(c) below to the Warrant Agent at the principal office of the Warrant Agent
or to the office of one of its agents as may be designated by the Warrant Agent from time to time. In the case of the Holder of
a Global Warrant, the Holder shall deliver the executed Exercise Notice and payment of the Exercise Price pursuant to Section 2(a)
of the Warrant. Notwithstanding any other provision in this Agreement, a holder whose interest in a Global Warrant is a beneficial
interest in a Global Warrant held in book-entry form through the Depositary (or another established clearing corporation performing
similar functions), shall effect exercises by delivering to the Depositary (or such other clearing corporation, as applicable)
the appropriate instruction form for exercise, complying with the procedures to effect exercise that are required by the Depositary
(or such other clearing corporation, as applicable). Upon giving irrevocable instructions to its Participant to exercise Warrants,
solely for purposes of Regulation SHO, the holder whose interest in the Warrant is a beneficial interest shall be deemed to have
exercised such Warrant, regardless of when the applicable Warrant Shares are delivered to such holder. The Company acknowledges
that the bank accounts maintained by the Warrant Agent in connection with the services provided under this Agreement will be in
its name and that the Warrant Agent may receive investment earnings in connection with the investment at Warrant Agent risk and
for its benefit of funds held in those accounts from time to time. Neither the Company nor the Holders will receive interest on
any deposits or Exercise Price.

 

(b) Upon receipt of an Exercise Notice for a cashless exercise
pursuant to Section 2(c) of the Warrant (each, a “Cashless Exercise”), the Company will promptly calculate
and transmit to the Warrant Agent the number of Warrant Shares issuable in connection with such Cashless Exercise and deliver a
copy of the Exercise Notice to the Warrant Agent, which shall issue such number of Warrant Shares in connection with such Cashless
Exercise.

 

(c) Upon the Warrant Agent’s receipt, at or prior to the
Close of Business on the Termination Date set forth in a Warrant, of the executed Exercise Notice, the payment of the Exercise
Price pursuant to Section 2(a) of the Warrant with respect to the shares to be purchased (other than in the case of a
Cashless Exercise), an amount equal to any applicable tax, governmental charge or expense reimbursement referred to in Section
6 in cash, or by wire transfer, certified check or bank draft payable to the order of the Company and, in the case of
an exercise of a Warrant in the form of a Warrant Certificate for some or all of the Warrant Shares represented thereby,
the Warrant Certificate (to the extent required pursuant to the Warrant), the Warrant Agent shall cause the Warrant Shares
underlying such Warrant to be delivered to or upon the order of the Holder of such Warrant, registered in such name or names as
may be designated by such Holder, no later than the Warrant Share Delivery Date. If the Company is then a participant in the DWAC
system of the Depositary and either (A) there is an effective registration statement permitting the issuance of the Warrant
Shares to or resale of the Warrant Shares by Holder or (B) the Warrant is being exercised via Cashless Exercise, then the
certificates for Warrant Shares shall be transmitted by the Warrant Agent to the Holder by crediting the account of the Holder’s
broker with the Depositary through its DWAC system. For the avoidance of doubt, if the Company becomes obligated to pay any amounts
to any Holders pursuant to Section 2(d)(i) or 2(d)(iv) of the Warrant, such obligation shall be solely that of the Company
and not that of the Warrant Agent. Notwithstanding anything else to the contrary in this Agreement, except in the case of a Cashless
Exercise, if any Holder fails to duly deliver payment to the Warrant Agent of an amount equal to the aggregate Exercise Price of
the Warrant Shares to be purchased upon exercise of such Holder’s Warrant as set forth in Section 7(a) hereof, the Warrant
Agent will not obligated to deliver certificates representing any such Warrant Shares (via DWAC or otherwise) until following receipt
of such payment, and the applicable Warrant Share Delivery Date shall be deemed extended by one day for each day (or part thereof)
until such payment is delivered to the Warrant Agent.

 

     

     

    

 

(d) The Warrant Agent shall deposit all funds received by it
in payment of the Exercise Price for all Warrants in the account of the Company maintained with the Warrant Agent for such purpose
(or to such other account as directed by the Company in writing) and shall advise the Company via telephone at the end of each
day on which funds for the exercise of any Warrant are received of the amount so deposited to its account. The Warrant Agent shall
promptly confirm such telephonic advice to the Company in writing.

 

(e) In case the Holder of any Warrant Certificate exercises
fewer than all Warrants evidenced thereby and surrenders such Warrant Certificate in connection with such partial exercise, a new
Warrant Certificate evidencing the number of Warrant Shares equivalent to the number of Warrant Shares remaining unexercised may
be issued by the Warrant Agent to the Holder of such Warrant Certificate or to his duly authorized assigns in accordance with Section 2(d)(ii)
of the Warrant, subject to the provisions of Section 6 hereof.

 

Section 8. Cancellation and Destruction of Warrant Certificates.
All Warrant Certificates surrendered for the purpose of exercise, transfer, split up, combination or exchange shall, if surrendered
to the Company or to any of its agents, be delivered to the Warrant Agent for cancellation or in canceled form, or, if surrendered
to the Warrant Agent, shall be canceled by it, and no Warrant Certificates shall be issued in lieu thereof except as expressly
permitted by any of the provisions of this Agreement. The Company shall deliver to the Warrant Agent for cancellation and retirement,
and the Warrant Agent shall so cancel and retire, any other Warrant Certificate purchased or acquired by the Company otherwise
than upon the exercise thereof. The Warrant Agent shall deliver all canceled Warrant Certificates to the Company, or shall, at
the written request of the Company, destroy such canceled Warrant Certificates, and in such case shall deliver a certificate of
destruction thereof to the Company, subject to any applicable law, rule or regulation requiring the Warrant Agent to retain such
canceled certificates.

 

Section 9. Certain Representations; Reservation and
Availability of Common or Cash.

 

(a) This Agreement has been duly authorized, executed and delivered
by the Company and, assuming due authorization, execution and delivery hereof by the Warrant Agent, constitutes a valid and legally
binding obligation of the Company enforceable against the Company in accordance with its terms, and the Warrants have been duly
authorized, executed and issued by the Company and, assuming due authentication thereof by the Warrant Agent pursuant hereto and
payment therefor by the Holders as provided in the Registration Statement, constitute valid and legally binding obligations of
the Company enforceable against the Company in accordance with their terms and entitled to the benefits thereof; in each case except
as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and other similar laws relating to or affecting
creditors’ rights generally or by general equitable principles (regardless of whether such enforceability is considered in
a proceeding in equity or at law).

 

(b) As of the date hereof and prior to the Offering, the authorized
capital stock of the Company consists of (i) an unlimited number of Common Shares, of which [ ] shares are issued and outstanding,
and [ ] Common Shares reserved for issuance upon exercise of the Warrants, inclusive of any Warrants the Underwriter may acquire
upon exercise of its over-allotment option described in the Registration Statement. Except as disclosed in the Registration Statement,
there are no other outstanding obligations, warrants, options or other rights to subscribe for or purchase from the Company any
class of capital stock of the Company.

 

(c) The Company covenants and agrees that it will cause to be
reserved and kept available out of its authorized and unissued Common Shares or its authorized and issued Common Shares held in
its treasury, free from preemptive rights, the number of Common Shares that will be sufficient to permit the exercise in full of
all outstanding Warrants.

 

(d) The Warrant Agent will create a special account for the
issuance of Common Shares upon the exercise of Warrants.

 

(e) The Company further covenants and agrees that it will pay
when due and payable any and all federal and state transfer taxes and charges which may be payable in respect of the original issuance
or delivery of the Warrant Certificates or certificates evidencing Common Shares upon exercise of the Warrants. The Company shall
not, however, be required to pay any tax or governmental charge which may be payable in respect of any transfer involved in the
transfer or delivery of Warrant Certificates or the issuance or delivery of certificates for Common Shares in a name other than
that of the Holder of the Warrant Certificate evidencing Warrants surrendered for exercise or to issue or deliver any certificate
for Common Shares upon the exercise of any Warrants until any such tax or governmental charge shall have been paid (any such tax
or governmental charge being payable by the Holder of such Warrant Certificate at the time of surrender) or until it has been established
to the Company’s reasonable satisfaction that no such tax or governmental charge is due.

 

     

     

    

 

Section 10. Common Shares Record Date. Each Holder
shall be deemed to have become the holder of record for the Warrant Shares pursuant to Section 2(d)(i) of the Warrants.

 

Section 11. Adjustment of Exercise Price, Number of
Common Shares or Number of the Company Warrants. The Exercise Price, the number of Common Shares covered by each Warrant and
the number of Warrants outstanding are subject to adjustment from time to time as provided in Section 3 of the Warrant. In
the event that at any time, as a result of an adjustment made pursuant to Section 3 of the Warrant, the Holder of any Warrant
thereafter exercised shall become entitled to receive any shares of the Company other than Common Shares, thereafter the number
of such other shares so receivable upon exercise of any Warrant shall be subject to adjustment from time to time in a manner and
on terms as nearly equivalent as practicable to the provisions with respect to the shares contained in Section 3 of the Warrant,
and the provisions of Sections 7, 9 and 13 of this Agreement with respect to the Common Shares shall apply on like terms to any
such other shares. All Warrants originally issued by the Company subsequent to any adjustment made to the Exercise Price pursuant
to the Warrant shall evidence the right to purchase, at the adjusted Exercise Price, the number of Common Shares purchasable from
time to time hereunder upon exercise of the Warrants, all subject to further adjustment as provided herein.

 

Section 12. Certification of Adjusted Exercise Price
or Number of Common Shares. Whenever the Exercise Price or the number of Common Shares issuable upon the exercise of each Warrant
is adjusted as provided in Section 11 or 13, the Company shall (a) promptly prepare a certificate setting forth the Exercise
Price of each Warrant as so adjusted, and a brief statement of the facts accounting for such adjustment, (b) promptly file
with the Warrant Agent and with each transfer agent for the Common Shares a copy of such certificate and (c) instruct the
Warrant Agent to send a brief summary thereof to each Holder of a Warrant.

 

Section 13. Fractional Common Shares.

 

(a) The Company shall not issue fractions of Warrants or distribute
a Global Warrant or Warrant Certificates that evidence fractional Warrants. Whenever any fractional Warrant would otherwise be
required to be issued or distributed, the actual issuance or distribution shall reflect a rounding of such fraction either up or
down to the nearest whole Warrant.

 

(b) The Company shall not issue fractions of Common Shares upon
exercise of Warrants or distribute stock certificates that evidence fractional Common Shares. Whenever any fraction of a Common
Share would otherwise be required to be issued or distributed, the actual issuance or distribution in respect thereof shall be
made in accordance with Section 2(d)(v) of the Warrant.

 

Section 14. Conditions of the Warrant Agent’s
Obligations. The Warrant Agent accepts its obligations herein set forth upon the terms and conditions hereof, including the
following to all of which the Company agrees and to all of which the rights hereunder of the Holders from time to time of the Warrant
shall be subject:

 

	 	(a)	
        Compensation and Indemnification. The Company agrees
promptly to pay the Warrant Agent the compensation detailed on Exhibit 2 hereto for all services rendered by the Warrant Agent
and to reimburse the Warrant Agent for reasonable out-of-pocket expenses (including reasonable counsel fees) incurred without
gross negligence, bad faith or willful misconduct by the Warrant Agent in connection with the services rendered hereunder by the
Warrant Agent. The Company also agrees to indemnify the Warrant Agent for, and to hold it harmless against, any loss, liability
or expense incurred without gross negligence, bad faith or willful misconduct on the part of the Warrant Agent, arising out of
or in connection with its acting as Warrant Agent hereunder, including the reasonable costs and expenses of defending against
any claim of such liability. 

 

     

     

    

 

	 	(b)	Agent for the Company. In acting under this Warrant Agreement and in connection with the Warrant Certificates, the Warrant Agent is acting solely as agent of the Company and does not assume any obligations or relationship of agency or trust for or with any of the Holders of Warrant Certificates or beneficial owners of Warrants. 

 

	 	(c)	Counsel. The Warrant Agent may consult with counsel satisfactory to it, which may include counsel for the Company, and the written advice of such counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in accordance with the advice of such counsel. 

 

	 	(d)	Documents. The Warrant Agent shall be protected and shall incur no liability for or in respect of any action taken or omitted by it in reliance upon any Warrant Certificate, notice, direction, consent, certificate, affidavit, statement or other paper or document reasonably believed by it to be genuine and to have been presented or signed by the proper parties. 

 

	 	(e)	Certain Transactions. The Warrant Agent, and its officers, directors and employees, may become the owner of, or acquire any interest in, Warrants, with the same rights that it or they would have if it were not the Warrant Agent hereunder, and, to the extent permitted by applicable law, it or they may engage or be interested in any financial or other transaction with the Company and may act on, or as depositary, trustee or agent for, any committee or body of Holders of Warrant Securities or other obligations of the Company as freely as if it were not the Warrant Agent hereunder. Nothing in this Warrant Agreement shall be deemed to prevent the Warrant Agent from acting as trustee under any indenture to which the Company is a party. 

 

	 	(f)	No Liability for Interest. Unless otherwise agreed with the Company, the Warrant Agent shall have no liability for interest on any monies at any time received by it pursuant to any of the provisions of this Agreement or of the Warrant Certificates. 

 

	 	(g)	No Liability for Invalidity. The Warrant Agent shall have no liability with respect to any invalidity of this Agreement or any of the Warrant Certificates (except as to the Warrant Agent’s countersignature thereon). 

 

	 	(h)	No Responsibility for Representations. The Warrant Agent shall not be responsible for any of the recitals or representations herein or in the Warrant Certificates (except as to the Warrant Agent’s countersignature thereon), all of which are made solely by the Company. 

 

	 	(i)	No Implied Obligations. The Warrant Agent shall be obligated to perform only such duties as are herein and in the Warrants specifically set forth and no implied duties or obligations shall be read into this Agreement or the Warrants against the Warrant Agent. The Warrant Agent shall not be under any obligation to take any action hereunder which may tend to involve it in any expense or liability, the payment of which within a reasonable time is not, in its reasonable opinion, assured to it. The Warrant Agent shall not be accountable or under any duty or responsibility for the use by the Company of any of the Warrants authenticated by the Warrant Agent and delivered by it to the Company pursuant to this Agreement or for the application by the Company of the proceeds of the Warrants. The Warrant Agent shall have no duty or responsibility in case of any default by the Company in the performance of its covenants or agreements contained herein or in the Warrants or in the case of the receipt of any written demand from a Holder of a Warrant Certificate with respect to such default, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law. 

 

Section 15. Purchase or Consolidation or Change of Name
of Warrant Agent. Any corporation into which the Warrant Agent or any successor Warrant Agent may be merged or with which it
may be consolidated, or any corporation resulting from any merger or consolidation to which the Warrant Agent or any successor
Warrant Agent shall be party, or any corporation succeeding to the corporate trust business of the Warrant Agent or any successor
Warrant Agent, shall be the successor to the Warrant Agent under this Agreement without the execution or filing of any paper or
any further act on the part of any of the parties hereto, provided that such corporation would be eligible for appointment as a
successor Warrant Agent under the provisions of Section 17. In case at the time such successor Warrant Agent shall succeed
to the agency created by this Agreement any of the Warrants shall have been countersigned but not delivered, any such successor
Warrant Agent may adopt the countersignature of the predecessor Warrant Agent and deliver such Warrants so countersigned; and in
case at that time any of the Warrants shall not have been countersigned, any successor Warrant Agent may countersign such Warrants
either in the name of the predecessor Warrant Agent or in the name of the successor Warrant Agent; and in all such cases such Warrants
shall have the full force provided in the Warrants and in this Agreement.

 

     

     

    

 

In case at any time the name of the Warrant Agent shall be changed
and at such time any of the Warrants shall have been countersigned but not delivered, the Warrant Agent may adopt the countersignature
under its prior name and deliver Warrants so countersigned; and in case at that time any of the Warrants shall not have been countersigned,
the Warrant Agent may countersign such Warrants either in its prior name or in its changed name; and in all such cases such Warrants
shall have the full force provided in the Warrants and in this Agreement.

 

Section 16. Duties of Warrant Agent. The Warrant
Agent undertakes the duties and obligations imposed by this Agreement upon the following terms and conditions, all of which the
Company, by its acceptance hereof, shall be bound:

 

(a) The Warrant Agent may consult with legal counsel reasonably
acceptable to the Company (who may be legal counsel for the Company), and the opinion of such counsel shall be full and complete
authorization and protection to the Warrant Agent as to any action taken or omitted by it in good faith and in accordance with
such opinion.

 

(b) Whenever in the performance of its duties under this Agreement
the Warrant Agent shall deem it necessary or desirable that any fact or matter be proved or established by the Company prior to
taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically
prescribed) may be deemed to be conclusively proved and established by a certificate signed by the Chief Executive Officer or Chief
Financial Officer of the Company; and such certificate shall be full authentication to the Warrant Agent for any action taken or
suffered in good faith by it under the provisions of this Agreement in reliance upon such certificate.

 

(c) Subject to the limitation set forth in Section 14,
the Warrant Agent shall be liable hereunder only for its own gross negligence, bad faith or willful misconduct, or for a breach
by it of this Agreement.

 

(d) The Warrant Agent shall not be liable for or by reason of
any of the statements of fact or recitals contained in this Agreement or in the Warrants (except its countersignature thereof)
by the Company or be required to verify the same, but all such statements and recitals are and shall be deemed to have been made
by the Company only.

 

(e) The Warrant Agent shall not be under any responsibility
in respect of the validity of this Agreement or the execution and delivery hereof (except the due execution hereof by the Warrant
Agent) or in respect of the validity or execution of any Warrant (except its countersignature thereof); nor shall it be responsible
for any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant; nor shall it be responsible
for the adjustment of the Exercise Price or the making of any change in the number of Common Shares required under the provisions
of Section 11 or 13 or responsible for the manner, method or amount of any such change or the ascertaining of the existence
of facts that would require any such adjustment or change (except with respect to the exercise of Warrants evidenced by Warrant
Certificates after actual notice of any adjustment of the Exercise Price); nor shall it by any act hereunder be deemed to make
any representation or warranty as to the authorization or reservation of any Common Shares to be issued pursuant to this Agreement
or any Warrant or as to whether any Common Shares will, when issued, be duly authorized, validly issued, fully paid and nonassessable.

 

(f) Each party hereto agrees that it will perform, execute,
acknowledge and deliver or cause to be performed, executed, acknowledged and delivered all such further and other acts, instruments
and assurances as may reasonably be required by the other party hereto for the carrying out or performing by any party of the provisions
of this Agreement.

 

(g) The Warrant Agent is hereby authorized to accept instructions
with respect to the performance of its duties hereunder from the Chief Executive Officer or Chief Financial Officer of the Company,
and to apply to such officers for advice or instructions in connection with its duties, and it shall not be liable and shall be
indemnified and held harmless for any action taken or suffered to be taken by it in good faith in accordance with instructions
of any such officer, provided Warrant Agent carries out such instructions without gross negligence, bad faith or willful misconduct.

 

(h) The Warrant Agent and any shareholder, director, officer
or employee of the Warrant Agent may buy, sell or deal in any of the Warrants or other securities of the Company or become pecuniarily
interested in any transaction in which the Company may be interested, or contract with or lend money to the Company or otherwise
act as fully and freely as though it were not Warrant Agent under this Agreement. Nothing herein shall preclude the Warrant Agent
from acting in any other capacity for the Company or for any other legal entity.

 

     

     

    

 

(i) The Warrant Agent may execute and exercise any of the rights
or powers hereby vested in it or perform any duty hereunder either itself or by or through its attorney or agents, and the Warrant
Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney or agents or for
any loss to the Company resulting from any such act, default, neglect or misconduct, provided reasonable care was exercised in
the selection and continued employment thereof.

 

Section 17. Change of Warrant Agent. The Warrant
Agent may resign and be discharged from its duties under this Agreement upon 30 days’ notice in writing sent to the Company
and to each transfer agent of the Common Shares, and to the Holders of the Warrant Certificates. The Company may remove the Warrant
Agent or any successor Warrant Agent upon 30 days’ notice in writing, sent to the Warrant Agent or successor Warrant Agent,
as the case may be, and to each transfer agent of the Common Shares, and to the Holders of the Warrant Certificates. If the Warrant
Agent shall resign or be removed or shall otherwise become incapable of acting, the Company shall appoint a successor to the Warrant
Agent. If the Company shall fail to make such appointment within a period of 30 days after such removal or after it has been notified
in writing of such resignation or incapacity by the resigning or incapacitated Warrant Agent or by the Holder of a Warrant Certificate
(who shall, with such notice, submit his Warrant Certificate for inspection by the Company), then the Holder of any Warrant Certificate
may apply to any court of competent jurisdiction for the appointment of a new Warrant Agent. Any successor Warrant Agent, whether
appointed by the Company or by such a court, shall be a corporation organized and doing business under the laws of the United States
or of a state thereof, in good standing, which is authorized under such laws to exercise corporate trust powers and is subject
to supervision or examination by federal or state authority and which has at the time of its appointment as Warrant Agent a combined
capital and surplus of at least $50,000,000. After appointment, the successor Warrant Agent shall be vested with the same powers,
rights, duties and responsibilities as if it had been originally named as Warrant Agent without further act or deed; but the predecessor
Warrant Agent shall deliver and transfer to the successor Warrant Agent any property at the time held by it hereunder, and execute
and deliver any further assurance, conveyance, act or deed necessary for the purpose. Not later than the effective date of any
such appointment, the Company shall file notice thereof in writing with the predecessor Warrant Agent and each transfer agent of
the Common Shares, and mail a notice thereof in writing to the Holders of the Warrant Certificates. However, failure to give any
notice provided for in this Section 17, or any defect therein, shall not affect the legality or validity of the resignation
or removal of the Warrant Agent or the appointment of the successor Warrant Agent, as the case may be.

 

Section 18. Issuance of New Warrants. Notwithstanding
any of the provisions of this Agreement or of the Warrants to the contrary, the Company may, at its option, issue a new Global
Warrant or Warrant Certificates, if any, evidencing Warrants in such form as may be approved by its Board of Directors to reflect
any adjustment or change in the Exercise Price per share and the number or kind or class of shares of stock or other securities
or property purchasable under the Global Warrant or Warrant Certificates, if any, made in accordance with the provisions of this
Agreement.

 

     

     

    

 

Section 19. Notices. Notices or demands authorized
by this Agreement to be given or made (i) by the Warrant Agent or by the Holder of any Warrant Certificate to or on the Company,
(ii) subject to the provisions of Section 17, by the Company or by the Holder of any Warrant Certificate to or on the
Warrant Agent or (iii) by the Company or the Warrant Agent to the Holder of any Warrant Certificate, shall be deemed given
(a) on the date delivered, if delivered personally, (b) on the first Business Day following the deposit thereof with
Federal Express or another recognized overnight courier, if sent by Federal Express or another recognized overnight courier, (c) on
the fourth Business Day following the mailing thereof with postage prepaid, if mailed by registered or certified mail (return receipt
requested), and (d) the date of transmission, if such notice or communication is delivered via facsimile or email attachment
at or prior to 5:30 p.m. (New York City time) on a Business Day and (e) the next Business Day after the date of transmission,
if such notice or communication is delivered via facsimile or email attachment on a day that is not a Business Day or later than
5:30 p.m. (New York City time) on any Business Day, in each case to the parties at the following addresses (or at such other address
for a party as shall be specified by like notice):

 

	 	(a)	If to the Company, to: 

 

XORTX Therapeutics Inc.

Suite 4000, 421 – 7th Avenue SW

Calgary, Alberta, Canada T2P 4K9

Attention: Charlotte May, Controller

Email: cmay@xortx.com

 

With a copy (for informational purposes only) to:

 

Dorsey & Whitney LLP

1400 Wewatta Street, Suite 400

Denver, CO 80202-5549

Attention: Anthony W. Epps, Esq.

Email: epps.anthony@dorsey.com

 

	 	(b)	If to the Warrant Agent, to: 

 

Continental Stock Transfer & Trust Company

1 State Street 30th Floor,

New York, NY 10004-1561

 

Attention: Compliance Department

 

For any notice delivered by email to be deemed given or made,
such notice must be followed by notice sent by overnight courier service to be delivered on the next business day following such
email, unless the recipient of such email has acknowledged via return email receipt of such email.

 

(c) If to the Holder of any Warrant Certificate, to the address
of such Holder as shown on the registry books of the Company. Any notice required to be delivered by the Company to the Holder
of any Warrant may be given by the Warrant Agent on behalf of the Company. Notwithstanding any other provision of this Agreement,
where this Agreement provides for notice of any event to a Holder of any Warrant Certificate, for a Global Warrant, such notice
shall be sufficiently given if given to the Depositary (or its designee) pursuant to the procedures of the Depositary or its designee.

 

Section 20. Supplements and Amendments.

 

(a) The Company and the Warrant Agent may from time to time
supplement or amend this Agreement without the approval of any Holders of Warrant Certificates in order to cure any ambiguity,
to correct or supplement any provision contained herein which may be defective or inconsistent with any other provisions herein,
or to make any other provisions with regard to matters or questions arising hereunder which the Company and the Warrant Agent may
deem necessary or desirable and which shall not adversely affect the interests of the Holders of the Warrants Certificates in any
material respect.

 

(b) In addition to the foregoing, with the consent of Holders
of Warrants, the Company and the Warrant Agent may modify this Agreement for the purpose of adding any provisions to or changing
in any manner or eliminating any of the provisions of this Warrant Agreement or modifying in any manner the rights of the Holders
of the Warrant Certificates; provided, however, that no modification of the terms (including but not limited to the
adjustments described in Section 11) upon which the Warrants are exercisable or reducing the percentage required for consent
to modification of this Agreement may be made without the consent of the Holder of each outstanding warrant certificate affected
thereby. As a condition precedent to the Warrant Agent’s execution of any amendment, the Company shall deliver to the Warrant
Agent a certificate from a duly authorized officer of the Company that states that the proposed amendment complies with the terms
of this Section 20.

 

Section 21. Successors. All covenants and provisions
of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure to the benefit of their respective
successors and assigns hereunder.

 

     

     

    

 

Section 22. Benefits of this Agreement. Nothing
in this Agreement shall be construed to give any Person other than the Company, the Holders of Warrants and the Warrant
Agent any legal or equitable right, remedy or claim under this Agreement; but this Agreement shall be for the sole and exclusive
benefit of the Company, the Warrant Agent, and the Holders of Warrants.

 

Section 23. Governing Law. This Agreement and each
Warrant issued hereunder shall be governed by, and construed in accordance with, the laws of the State of New York without giving
effect to the conflicts of law principles thereof.

 

Section 24. Counterparts. This Agreement may be
executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all
such counterparts shall together constitute but one and the same instrument.

 

Section 25. Captions. The captions of the sections
of this Agreement have been inserted for convenience only and shall not control or affect the meaning or construction of any of
the provisions hereof.

 

Section 26. Information. The Company agrees to promptly
provide to the Holders of the Warrants any information it provides to all holders of the Common Shares, except to the extent any
such information is publicly available on the EDGAR system (or any successor thereof) of the Securities and Exchange Commission.

 

Section 27. Force Majeure. Notwithstanding anything
to the contrary contained herein, Warrant Agent shall not be liable for any delays or failures in performance resulting from acts
beyond its reasonable control including, without limitation, acts of God, terrorist acts, shortage of supply, breakdowns or malfunctions,
interruptions or malfunction of computer facilities, or loss of data due to power failures or mechanical difficulties with information
storage or retrieval systems, labor difficulties, war, or civil unrest, it being understood that the Warrant Agent shall use reasonable
best efforts which are consistent with accepted practices in the banking industry to resume performance as soon as practicable
under the circumstances.

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement
to be duly executed as of the day and year first above written.

 

	 	XORTX THERAPEUTICS INC.
	 	 
	 	By:  	            
	 	Name:
	 	Title: 

	 	 	 
	 	CONTINENTAL STOCK TRANSFER & TRUST COMPANY
	 	 
	 	By:  	      
	 	Name:
	 	Title:

 

     

     

    

 

Annex A: Form of Warrant Certificate
Request Notice 

 

WARRANT CERTIFICATE REQUEST NOTICE

 

To: Continental Stock Transfer & Trust Company as Warrant
Agent for XORTX Therapeutics Inc. (the “Company”)

 

The undersigned Holder of Warrants (“Warrants”)
in the form of Global Warrants issued by the Company hereby elects to receive a Warrant Certificate evidencing the Warrants held
by the Holder as specified below:

 

1. Name of Holder of Warrants in form of Global Warrants: _____________________________

 

2. Name of Holder in Warrant Certificate (if different from
name of Holder of Warrants in form of Global Warrants): ________________________________

 

3. Number of Warrants in name of Holder in form of Global Warrants:
___________________

 

4. Number of Warrants for which Warrant Certificate shall be
issued: __________________

 

5. Number of Warrants in name of Holder in form of Global Warrants
after issuance of Warrant Certificate, if any: ___________

 

6. Warrant Certificate shall be delivered to the following address:

 

	 
	 
	
        

         

	 
	
          

	 
	
          

 

The undersigned hereby acknowledges and agrees that, in connection
with this Warrant Exchange and the issuance of the Warrant Certificate, the Holder is deemed to have surrendered the number of
Warrants in form of Global Warrants in the name of the Holder equal to the number of Warrants evidenced by the Warrant Certificate.

 

[SIGNATURE OF HOLDER]

 

Name of Investing Entity: ____________________________________________________

 

Signature of Authorized Signatory of Investing Entity:
______________________________

 

Name of Authorized Signatory: ________________________________________________

 

Title of Authorized Signatory: _________________________________________________

 

Date: _______________________________________________________________

 

     

     

    

 

Exhibit 1: Form of Common Share
Warrant

 

     

     

    

 

Exhibit 2: Form of Pre-funded Warrant

 

     

     

    

 

Exhibit 3: Form of Underwriter Warrant

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]